Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing

Deyi, Véronique Yvette Miendje; Burette, A; Bentatou, Zahra; Maaroufi, Younes; Bontems, Patrick; Lepage, Philippe

doi:10.1016/j.diagmicrobio.2011.05.002

Cited by 37 publications

(26 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The presence of multiple mutations in the 23S rRNA gene for clarithromycin was found in 8.9% of the samples. Similar results were also reported in Belgium, where multiple mutations were found in 25% of samples for fluoroquinolones and 12% for clarithromycin[19]. Finally, simultaneous resistance to both antibiotics was unusual (4.3%) in our study, similar to what was reported in South Africa (2.5%)[22], Hong Kong (3.7%)[36], Italy (1.6%)[37], and Spain (4%)[38].…”

Section: Discussionsupporting

confidence: 86%

“…In clarithromycin-resistant samples, the A2147G mutation (90.4%) was prevalent, as was found in previous Brazilian studies[23,28] and in studies in other countries, such as France (83.5%)[13] and Belgium (80%)[19]. Among the 13.5% (66/490) fluoroquinolone-resistant samples studied, 37.9% (25/66) presented a mutant codon that could not be identified by the GenoType HelicoDR method, and the D91N mutation was found in 34.8% (23/66) of samples.…”

Section: Discussionsupporting

confidence: 74%

“…The equipment for carrying out this test is usually already available in molecular biology laboratories[18]. Comparative studies carried out in different countries, including Brazil, reported agreement above 90% between the phenotypic and genotypic methods[13,19,22-24]. …”

Section: Discussionmentioning

confidence: 99%

“…European studies have recently validated a new molecular test that combines PCR and hybridization, allowing for the rapid detection of bacterial resistance to both clarithromycin and fluoroquinolones[13,19]. This novel GenoType HelicoDR (Hain Life Science, Germany) test involves a DNA strip coated with different specific primers (probes) designed to hybridize with the wild-type allele or reveal mutant sequences[13].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Detection ofHelicobacter pyloriresistance to clarithromycin and fluoroquinolones in Brazil: A national survey

Sanches¹,

Martins²,

Lima³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo evaluate bacterial resistance to clarithromycin and fluoroquinolones in Brazil using molecular methods.METHODSThe primary antibiotic resistance rates of Helicobacter pylori (H. pylori) were determined from November 2012 to March 2015 in the Southern, South-Eastern, Northern, North-Eastern, and Central-Western regions of Brazil. Four hundred ninety H. pylori patients [66% female, mean age 43 years (range: 18-79)] who had never been previously treated for this infection were enrolled. All patients underwent gastroscopy with antrum and corpus biopsies and molecular testing using GenoType HelicoDR (Hain Life Science, Germany). This test was performed to detect the presence of H. pylori and to identify point mutations in the genes responsible for clarithromycin and fluoroquinolone resistance. The molecular procedure was divided into three steps: DNA extraction from the biopsies, multiplex amplification, and reverse hybridization.RESULTSClarithromycin resistance was found in 83 (16.9%) patients, and fluoroquinolone resistance was found in 66 (13.5%) patients. There was no statistical difference in resistance to either clarithromycin or fluoroquinolones (P = 0.55 and P = 0.06, respectively) among the different regions of Brazil. Dual resistance to clarithromycin and fluoroquinolones was found in 4.3% (21/490) of patients. The A2147G mutation was present in 90.4% (75/83), A2146G in 16.9% (14/83) and A2146C in 3.6% (3/83) of clarithromycin-resistant patients. In 10.8% (9/83) of clarithromycin-resistant samples, more than 01 mutation in the 23S rRNA gene was noticed. In fluoroquinolone-resistant samples, 37.9% (25/66) showed mutations not specified by the GenoType HelicoDR test. D91N mutation was observed in 34.8% (23/66), D91G in 18.1% (12/66), N87K in 16.6% (11/66) and D91Y in 13.6% (9/66) of cases. Among fluoroquinolone-resistant samples, 37.9% (25/66) showed mutations not specified by the GenoType HelicoDR test.CONCLUSIONThe H. pylori clarithromycin resistance rate in Brazil is at the borderline (15%-20%) for applying the standard triple therapy. The fluoroquinolone resistance rate (13.5%) is equally concerning.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 74%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Detection ofHelicobacter pyloriresistance to clarithromycin and fluoroquinolones in Brazil: A national survey

Sanches¹,

Martins²,

Lima³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…The GenoType HelicoDR assay allows for the molecular genetic identification of H. pylori and its resistance to clarithromycin and fluoroquinolones, such as levofloxacin. The assay has been reported to be efficient at detecting mutations predictive of antibiotic resistance when applied to H. pylori cultures or gastric biopsy specimens[13-16], with a sensitivity and specificity of 94%-100% and 86%-99% for detecting clarithromycin resistance and 83%-87% and 95%-98.5% for detecting fluoroquinolone resistance, respectively[16,17]. …”

Section: Introductionmentioning

confidence: 99%

Molecular detection ofHelicobacter pyloriantibiotic resistance in stoolvsbiopsy samples

Brennan¹,

Omorogbe²,

Hussey³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo compare (1) demographics in urea breath test (UBT) vs endoscopy patients; and (2) the molecular detection of antibiotic resistance in stool vs biopsy samples.METHODSSix hundred and sixteen adult patients undergoing endoscopy or a UBT were prospectively recruited to the study. The GenoType HelicoDR assay was used to detect Helicobacter pylori (H. pylori) and antibiotic resistance using biopsy and/or stool samples from CLO-positive endoscopy patients and stool samples from UBT-positive patients.RESULTSInfection rates were significantly higher in patients referred for a UBT than endoscopy (overall rates: 33% vs 19%; treatment-naïve patients: 33% vs 14.7%, respectively). H. pylori-infected UBT patients were younger than H. pylori-infected endoscopy patients (41.4 vs 48.4 years, respectively, P < 0.005), with a higher percentage of H. pylori-infected males in the endoscopy-compared to the UBT-cohort (52.6% vs 33.3%, P = 0.03). The GenoType HelicoDR assay was more accurate at detecting H. pylori infection using biopsy samples than stool samples [98.2% (n = 54/55) vs 80.3% (n =53/66), P < 0.005]. Subset analysis using stool and biopsy samples from CLO-positive endoscopy patients revealed a higher detection rate of resistance-associated mutations using stool samples compared to biopsies. The concordance rates between stool and biopsy samples for the detection of H. pylori DNA, clarithromycin and fluoroquinolone resistance were just 85%, 53% and 35%, respectively.CONCLUSIONDifferences between endoscopy and UBT patients provide a rationale for non-invasive detection of H. pylori antibiotic resistance. However, the GenoType HelicoDR assay is an unsuitable approach.

show abstract

Diagnosis of Helicobacter pylori infection

Tonkić

Vuković

Cindro

et al. 2018

Wien Klin Wochenschr

View full text Add to dashboard Cite

Helicobacter pylori infections represent an important factor in the pathogenesis of chronic gastritis, peptic ulcer, MALT lymphoma and gastric adenocarcinoma. The recently published Maastricht V/Florence consensus report indicated that the urea breath test using 13 C urea still remains the best non-invasive test to diagnose H. pylori infections with high sensitivity and specificity. Among the stool antigen tests, the ELISA monoclonal antibody test is a rational option. Effective therapy should be based only on susceptibility testing in regions with documented high clarithromycin resistance (>15%). Advanced high-resolution endoscopic technologies enable increased diagnostic accuracy for detection of H. pylori infections.

show abstract

Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing

Cited by 37 publications

References 14 publications

Detection ofHelicobacter pyloriresistance to clarithromycin and fluoroquinolones in Brazil: A national survey

Detection ofHelicobacter pyloriresistance to clarithromycin and fluoroquinolones in Brazil: A national survey

Molecular detection ofHelicobacter pyloriantibiotic resistance in stoolvsbiopsy samples

Diagnosis of Helicobacter pylori infection

Contact Info

Product

Resources

About